In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Georg Vo Beiske, CEO, Tribune Therapeutics

Jonas Hallén, Co-Founder & CMO, Calluna Pharma

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.